Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has been assigned an average rating of “Hold” from the twenty-one research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $140.90.

Several research analysts have weighed in on the company. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Canaccord Genuity Group cut their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Stephens reiterated an “overweight” rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Finally, Citigroup decreased their price target on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th.

Illumina Stock Performance

Shares of ILMN stock opened at $74.16 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a 50-day moving average of $96.82 and a 200-day moving average of $125.10. Illumina has a one year low of $70.64 and a one year high of $156.66. The company has a market cap of $11.75 billion, a P/E ratio of -9.66, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Institutional Trading of Illumina

Several large investors have recently added to or reduced their stakes in the stock. Bank of Stockton lifted its position in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after purchasing an additional 80 shares during the period. Stephens Inc. AR boosted its position in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares in the last quarter. Spire Wealth Management grew its holdings in shares of Illumina by 26.0% during the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock worth $63,000 after acquiring an additional 97 shares during the period. IFP Advisors Inc lifted its stake in shares of Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after purchasing an additional 99 shares during the period. Finally, Freedom Investment Management Inc. boosted its position in shares of Illumina by 3.7% during the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock valued at $382,000 after purchasing an additional 101 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.